In a research note to investors, Wells Fargo & Co. Upgraded on Myriad Genetics, Inc. (NASDAQ:MYGN) with an Outperform and no price target.
On a consensus level, sell-side research analysts have a consensus price target of 35.00 on the stock. This is the average of the individual targets from the covering analysts polled by Thomson Reuters First Call. Analysts are projecting that the company will report earnings per share of 0.42 for next quarter. For the current year, research firms are anticipating earnings of 1.63 per share.
On a technical level the stock has a 50 Day Moving Average of 33.57. Based on a recent trade, this puts the equity at +0.40% away from that average. In comparing the stock’s current level to its extended history, the stock is trading -15.64% away from its 52 week high of 39.95 and +11.22% away from the stock’s low point over the past 52 weeks, which was 30.30.
The price to earnings ratio, or the valuation ratio of a company’s current share price compared to its per-share earnings sits at 31.20. This is an important indicator as a higher ratio typically suggests that investors are expecting higher future earnings growth compared to companies in the same industry with lower price to earnings ratios. When calculating in the EPS estimates for the current year from sell-side analysts, the Price to current year EPS stands at 20.67. Investors looking further ahead, will note that the Price to next year’s EPS is 18.72.
Today the stock opened the current trading session at 32.98 and at the time of writing the last Bid was at 33.70. In the current session the stock reached as high as 34.40 and dipped down to 32.62. Myriad Genetics, Inc., a NMS listed company, has a current market cap of 2.31B and on average over the past 3 months has seen 708533 shares trade hands on a daily basis.